Crestwood Advisors Group LLC boosts Johnson & Johnson holdings in third quarter by 1.0%

☀️Trending News

Johnson & Johnson ($NYSE:JNJ) is a multinational corporation that specializes in the development, manufacturing, and selling of pharmaceuticals, medical devices, and consumer packaged goods. Johnson & Johnson’s stock is listed on the New York Stock Exchange under the ticker symbol JNJ. The company’s portfolio includes popular brands such as Band-Aid, Tylenol, and Neutrogena, as well as prescription drugs like Remicade and Zytiga.

In addition, Johnson & Johnson also produces medical devices such as surgical tools and equipment for diabetes management. Its wide range of products and strong brand reputation have contributed to the company’s success over the years. This was reflected in the company’s latest Form 13F filing, a quarterly report of institutional investment managers’ holdings in publicly traded companies. The decision to boost its holdings in Johnson & Johnson may be attributed to the company’s strong financial performance and potential for future growth. This was driven by strong demand for its pharmaceutical products and medical devices, as well as growth in its consumer health segment. Furthermore, Johnson & Johnson has a robust pipeline of new products in development, particularly in its pharmaceutical division. The company has a track record of bringing successful drugs to market, and investors may see potential for continued growth and profitability in the future. With its diverse portfolio of products and ongoing innovation, Johnson & Johnson remains a strong player in the healthcare industry and a popular choice among investors.

Analysis

As an analyst at GoodWhale, I have thoroughly examined the financials of JOHNSON & JOHNSON and have come to some key conclusions. This indicates that the company has a healthy cash flow and manageable debt, which puts it in a good position to weather any financial crises. This is a positive sign for potential investors as it shows that the company is capable of sustaining its operations even in difficult times. In terms of its financial performance, JOHNSON & JOHNSON is strong in dividend and profitability, with a proven track record of consistently paying out dividends to its shareholders. This makes it an attractive option for income-seeking investors. However, it is important to note that JOHNSON & JOHNSON is only medium in terms of its assets and weak in growth. This means that while the company is stable and profitable, it may not offer high growth potential for investors seeking capital appreciation. Based on our analysis, JOHNSON & JOHNSON can be classified as a ‘cow’ company. This means that it has a strong history of consistently paying out dividends and is likely to continue doing so in the future. This type of company is attractive to investors who prioritize consistent and sustainable returns rather than high-risk, high-growth opportunities. In conclusion, JOHNSON & JOHNSON may be a suitable investment for income-seeking investors who value stability and consistency over growth potential. Its solid financial health and track record of dividends make it a reliable option for those looking for long-term returns. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for JNJ. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for JNJ. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for JNJ. More…

Key Ratios Snapshot

Some of the financial key ratios for JNJ are shown below. More…

Peers

The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.

– AstraZeneca PLC ($LSE:AZN)

AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.

– BioNTech SE ($NASDAQ:BNTX)

BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.

Summary

Crestwood Advisors Group LLC, an investment firm, grew its position in Johnson & Johnson by 1.0% in the third quarter. This indicates the firm’s confidence in the company’s growth potential and financial stability. Johnson & Johnson is a well-known consumer healthcare company, but the focus here is on the investment aspect.

Crestwood’s decision to increase its stake in Johnson & Johnson could be based on various factors such as positive earnings outlook, strong balance sheet, and dividend payments. This analysis suggests that the firm sees Johnson & Johnson as a prudent investment choice with potential for long-term returns.